Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exact Sciences : UBS Adjusts Exact Sciences PT to $154 From $140, Maintains Neutral Rating

02/18/2021 | 11:24am EDT


© MT Newswires 2021
All news about EXACT SCIENCES CORPORATION
04/08EXACT SCIENCES  : schedules first quarter 2021 earnings call
PR
04/06EXACT SCIENCES  : Significant Insider Selling Continues at Exact Sciences (EXAS)
MT
04/05INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Exact Sciences
MT
04/01EXACT SCIENCES  : New NCCN Breast Cancer Guidelines Recognize Oncotype DX Breast..
PU
03/29SomaLogic to Go Public Through Combination With SPAC
MT
03/03INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Exact Sciences
MT
02/18EXACT SCIENCES  : UBS Adjusts Exact Sciences PT to $154 From $140, Maintains Neu..
MT
02/17EXACT SCIENCES  : Cowen & Co Adjusts Exact Sciences PT to $180 From $150, Mainta..
MT
02/17EXACT SCIENCES  : SVB Leerink Adjusts Exact Sciences' Price Target to $180 From ..
MT
02/16EXACT SCIENCES  : Management's Discussion and Analysis of Financial Condition an..
AQ
More news
Financials (USD)
Sales 2021 1 733 M - -
Net income 2021 -586 M - -
Net Debt 2021 776 M - -
P/E ratio 2021 -36,7x
Yield 2021 -
Capitalization 21 228 M 21 228 M -
EV / Sales 2021 12,7x
EV / Sales 2022 10,3x
Nbr of Employees 4 900
Free-Float 93,4%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Average target price 165,69 $
Last Close Price 125,54 $
Spread / Highest target 80,0%
Spread / Average Target 32,0%
Spread / Lowest Target -39,5%
EPS Revisions
Managers and Directors
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Chief Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION-3.01%21 228
GUARDANT HEALTH, INC.21.95%15 784
BGI GENOMICS CO., LTD.-5.19%8 067
INVITAE CORPORATION-9.11%7 473
ADAPTIVE BIOTECHNOLOGIES CORPORATION-31.64%5 627
IOVANCE BIOTHERAPEUTICS, INC.-34.94%4 437